Canada Markets closed

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2900-0.1000 (-7.19%)
At close: 04:00PM EDT
1.3200 +0.03 (+2.33%)
After hours: 06:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.3900
Open1.3900
Bid1.2700 x 1400
Ask1.3200 x 800
Day's Range1.2500 - 1.4200
52 Week Range1.2500 - 68.4000
Volume334,782
Avg. Volume376,892
Market Cap156.601M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference

    PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL. Details on the Company presentation are as follows: Event:H.C. Wainwright Global Investment ConferenceDate:Tuesday, May 24, 2022Time:10:00-10:30 am ET The H.C. Wainwright Global Investment Conference w

  • GlobeNewswire

    Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30 p.m. ET PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2022 and provided a corporate updat

  • GlobeNewswire

    Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

    PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla® (levonorgestrel and ethinyl estradiol) transdermal system (LNG/EE TDS). The contraceptive transdermal delivery system was approved by the U.S. Food and Drug Administration (“FDA”) in February 2020 as a method of contraception for use in women of reproducti